- Trial phase
- Phase 2
- Time to market
- If Phase 2 succeeds, Phase 3 trials would follow, meaning potential FDA approval is likely several years away (probably 2029 or later under an optimistic scenario).
- Why 3/10
- The next hard catalyst is the NORLIGHT Phase 2 topline readout, guided for the second half of 2027 (more than 6 months away). ACP-211 is an early-stage pipeline asset at a company with two approved, revenue-generating drugs (DAYBUE and NUPLAZID) and several other pipeline programs, so this single drug is not a major value driver for the stock.
The next catalyst for ACP-211 is the NORLIGHT Phase 2 topline readout, guided for the second half of 2027 (roughly 8-13 months away). A positive efficacy and safety readout would validate the oral deuterated norketamine approach and open a large addressable market in MDD/TRD. A negative or equivocal result would likely end the program but would not threaten ACADIA's core value, which rests on its commercial-stage DAYBUE and NUPLAZID franchises.
Price Chart
Executive Summary
ACP-211 is ACADIA Pharmaceuticals' Phase 2 oral, once-daily, deuterated form of R-norketamine being developed as a monotherapy for major depressive disorder (MDD), including treatment-resistant depression (TRD). It is an NMDA receptor antagonist designed to improve upon the ketamine class by enabling oral administration with a potentially longer half-life via deuteration. The NORLIGHT Phase 2 trial (NCT07284667) is currently recruiting at 26 US sites with primary completion estimated in August 2027. On the Q3 2026 earnings call (Nov 4, 2026), management guided for a Phase 2 topline readout in the second half of 2027. ACP-211 is one of several early-to-mid-stage pipeline assets at ACADIA, which generates substantial revenue from two approved drugs (DAYBUE for Rett syndrome and NUPLAZID for Parkinson's disease psychosis). The drug faces competition from Johnson & Johnson's approved Spravato (esketamine nasal spray) and other ketamine-class developers.
How It Works
ACP-211 is an oral pill that blocks the NMDA receptor, a protein on brain cells involved in mood regulation. It is a selectively deuterated (chemically modified to slow breakdown in the body) form of R-norketamine, which is a metabolite of ketamine. The deuteration is intended to extend the drug's half-life enough to make a convenient once-daily oral pill feasible, unlike Johnson & Johnson's Spravato, which requires in-clinic nasal spray administration.
Trial Status
The NORLIGHT trial (NCT07284667) is a double-blind, placebo-controlled, parallel-group Phase 2 study evaluating ACP-211 monotherapy in adults with MDD who have had an inadequate response to antidepressant treatment, including treatment-resistant depression. The trial is actively recruiting at 26 sites across the United States. Estimated enrollment is 153 participants. Primary completion is estimated in August 2027.
The Two-Sided Case
Upcoming Catalysts
- NORLIGHT Phase 2 topline readout for ACP-211 in MDD/TRD expected in the second half of 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ACADIA PHARMACEUTICALS INC 8-K ACAD ·Originating report